Cuproptosis regulatory genes greatly contribute to clinical assessments of hepatocellular carcinoma

BMC Cancer

Research

Changwei Ke¹  Jia Yuan²  Shuting Fan²  Shejiao Dai²  Longbao Yang³  Yong Li³  Yang Chen⁴  Fangshi Xu⁴ 

[1] Department of Emergency, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi Province, China;Department of Gastroenterology, The Second Affiliated Hospital of Xi’an Jiaotong University, No. 157, West Five Road, 710004, Xi’an, Shaanxi, China;Department of Gastroenterology, The Second Affiliated Hospital of Xi’an Jiaotong University, No. 157, West Five Road, 710004, Xi’an, Shaanxi, China;Department of Outpatient, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi Province, China;Department of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi Province, China;

关键词: Cuproptosis;    Hepatocellular carcinoma;    Risk signature;    Prognosis;    DLAT;   

DOI  :  10.1186/s12885-022-10461-2

 received in 2022-06-16, accepted in 2022-12-19,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundHepatocellular carcinoma (HCC) is a common abdominal cancer with dissatisfactory therapeutic effects. The discovery of cuproptosis lights on new approach for cancer treatment and assessment. So far, there is extremely limited research investigating the roles of cuproptosis-related (CR) genes in cancers.MethodsA novel CR risk signature was constructed using the Lasso regression analysis. Its prognostic value was assessed via a series of survival analyses and validated in three GEO cohorts. The effects of CR risk signature on tumor immune microenvironment (TIM) were explored through CIBERSORT, ESTIMATE, and ssGSEA algorithms. Using GESA, we investigated its impacts on various metabolism process. The somatic mutation features of CR signature genes were also explored via cBioPortal database. Using tumor mutation burden, expressions of immune checkpoints, TIDE score, IMvigor 210 cohort, and GSE109211 dataset, we explored the potential associations of CR risk score with the efficacy of immune checkpoint inhibitors (ICIs) and sorafenib. Finally, the biofunctions of DLAT in HCC cells were ascertained through qPCR, immunohistochemistry, colony formation, and Transwell assays.ResultsFDX1, DLAT, CDKN2A and GLS constituted the CR risk signature. CR risk signature possessed high prognostic value and was also applicable to three validation cohorts. Meanwhile, it could improve the accuracy and clinical making-decision benefit of traditional prognostic model. Moreover, high CR risk was indicative of unfavorable anti-tumor immune response and active metabolisms of glycolysis and nucleotide. As for therapeutic correlation, CR risk score was a potential biomarker for predicting the efficacy of ICIs and sorafenib. Through qPCR and immunohistochemistry detection in clinical samples, we reconfirmed DLAT was significantly upregulated in HCC samples. Overexpression of DLAT could promote the proliferation, migration, and invasion of HepG2 and HuH-7 cells.ConclusionsThe novel CR risk signature greatly contributed to the clinical assessment of HCC. Cuproptosis regulatory gene DLAT possessed cancer-promoting capacities and was expected to be a promising therapeutic target for HCC.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq319.gif

41116_2022_35_Article_IEq318.gif

41116_2022_35_Article_IEq317.gif

41116_2022_35_Article_IEq316.gif

41116_2022_35_Article_IEq273.gif

41116_2022_35_Article_IEq270.gif

41116_2022_35_Article_IEq250.gif

Fig. 1

41116_2022_35_Article_IEq231.gif

Fig. 4

41116_2022_35_Article_IEq147.gif

41116_2022_35_Article_IEq131.gif

41116_2022_35_Article_IEq124.gif

41116_2022_35_Article_IEq108.gif

Fig. 6

40854_2022_443_Article_IEq20.gif

Fig. 1